Cingulate Inc. (CING) announced it was issued a European patent for lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder. The patent will include up to 30 European territories, including the United Kingdom.
"We look forward to obtaining additional patents in the near-term as we continue to showcase the clinical success of CTx-1301 and move closer to filing a new drug application with the FDA," said Cingulate Chairman and CEO Shane Schaffer.
Shares of Cingulate are up 119% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.